Cargando…
A Review of Oral Semaglutide Available Evidence: A New Era of Management of Diabetes with Peptide in a Pill Form
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have gained an important place in the management of diabetes management because of their exceptional glucose-lowering, weight lowering and cardiovascular (CV) benefits. Despite recommendations by various clinical practice guidelines and benefits,...
Autores principales: | Kalra, Sanjay, Das, Sambit, Zargar, Abdul H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302409/ https://www.ncbi.nlm.nih.gov/pubmed/35873937 http://dx.doi.org/10.4103/ijem.ijem_522_21 |
Ejemplares similares
-
A Peptide in a Pill – Oral Semaglutide in the Management of Type 2 Diabetes
por: Selvarajan, Raja, et al.
Publicado: (2023) -
Oral Semaglutide: Dosage in Special Situations
por: Kalra, Sanjay, et al.
Publicado: (2022) -
A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
por: Kalra, Sanjay, et al.
Publicado: (2020) -
A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes
por: Aroda, Vanita R., et al.
Publicado: (2022) -
Oral Semaglutide
por: Bui, Vinh, et al.
Publicado: (2018)